People who take Selective Serotonin Reuptake Inhibitors (SSRIs) are twice as likely to have dental implants fail as those who are not taking SSRIs. SSRIs are the most common type of drug for depression treatment.
A recent article from the International and American Associations for Dental Research shows that the drug plays a key role in decreasing bone formation and heightening the risk of bone fracture. As bone metabolism influences osseointegration or dental implantation, the article looks at the relationship between SSRIs and osseointegrated implant failures.
From January 2007 to January 2013, the dental research associations studied 916 dental implants in 490 patients who were treated with dental implants. There were 51 patients in the study who were using SSRIs. These patients had a total of 94 implants. The researchers used data analysis that included generalized estimating equation models, cox proportional hazards, and Kaplan-Meier. After anywhere between three and 67 months of follow ups, 784 implants succeeded while 38 implants failed in the non-SSRI user group and 84 succeeded while 10 failed in the SSRI user group.
The takeaway from this study was that in comparison to non-SSRI users, SSRI users had a higher risk of dental implant failure (HR=2.31; P<0.01). The non-SSRI user group had a failure rate of 4.6 percent while the SSRI user group had a failure rate of 10.6 percent. Other factors associated with a higher risk of dental implant failure include smoking habits (P<0.01), bone augmentation (P=0.04), and small implant diameters (P=0.01 for 4mm or less).